Sprint Caffeine, Lost Lean Mass and a Too-Eager Atlantic Collapse
Six new papers, honestly explained: Caffeine and the sprint start · Weight-loss drugs and lean mass · Waistlines in seventy countries · Cholesterol drugs and first heart attacks · Is the Atlantic too fragile in models? · A nickel superconductor without pressure.
Chapters
The papers
- Caffeine dose and 100-m sprint phases (PLoS ONE)
- Incretin drugs and lean body mass (Cureus)
- Excess adiposity in 70 countries (eClinicalMedicine)
- Lipid-lowering therapies for primary prevention (eClinicalMedicine)
- Is AMOC collapse too unstable in models? (arXiv)
- Bulk ambient-pressure superconductivity in La5Ni4O10 (arXiv)
Transcript
The script the two AI voices read from. The times are worked out from the script, not heard, so a line can start a few seconds early or late.
Read the whole episode
Sponsor
Host 1Support for the Hastrup Review of Science comes from RefurbMiner.
Host 1One intelligent platform for your whole business. Invoicing, banking, and compliance in a single system, with every decision fully traceable. Privacy ready, and hosted in Europe.
Host 2Start your free fourteen day trial today. The link is in the show notes.
Cold open
Host 1Welcome to the Hastrup Review of Science — where artificial intelligence reads real science, so you don't have to pretend you understood the paper.
Host 1This week's lead is a controlled trial on how much caffeine a trained sprinter actually needs.
Host 2The answer is measurable, and most of the gain comes from less caffeine than many athletes take.
Caffeine and the sprint start
Host 1First, a sprinter's question. If caffeine before a race helps, does a double dose help twice as much?
Host 2A group at Beijing Sport University tested that in twenty-one trained male sprinters. Each man did three sessions at least a week apart: placebo, three milligrams of caffeine per kilogram of body weight, and six, double-blind and in randomised order. An hour after the capsule they ran two all-out sixty-metre sprints, then jumps and a ten-second bike sprint.
Host 1How much faster did they get, and is that a big number or a small one?
Host 2Over sixty metres, the lower dose cut about twelve hundredths of a second and the higher dose about seventeen and a half. The extra dose added roughly five hundredths at sixty metres and helped jump height and force in the blocks, but not the first ten metres or reaction time. Most of the gain already comes at three milligrams.
Host 1What should a listener be careful about before changing their own race routine?
Host 2The trial was registered about three weeks after the sprinters were enrolled, not before; the authors say nothing was changed. There was no power calculation, testing stopped at sixty metres, and side effects, sleep and whether the men could tell caffeine from placebo were not measured. Twenty-one men averaging twenty years old is a small sample, and none of them was forty.
Host 1So the low dose does most of the work, and the high dose buys a little more in specific places. The full story is in this paper's deep dive, out this week in the feed.
Weight-loss drugs and lean mass
Host 1Next, the muscle question behind the new weight-loss injections. When people lose weight on these drugs, how much of what they lose is not fat?
Host 2A preregistered systematic review pooled randomised trials that measured lean mass with a body scan called DXA, after roughly one to one and a half years. Against placebo, people on tirzepatide lost about eight percentage points more of their starting lean mass, and on semaglutide at the obesity dose about six. In kilograms that is roughly four and a half extra for tirzepatide, three and a half for semaglutide, and almost six for mazdutide.
Host 1Lean mass sounds like muscle. Is it the same thing?
Host 2No, and the authors are careful about it. Scan lean mass includes water, organs and connective tissue, so a loss on the scan is not proof of weaker muscles or frailty, and no pooled result here measured strength.
Host 1Can they tell us which drug is gentlest on muscle?
Host 2They tried, and concluded no. Only three comparisons were precise enough, the head-to-head estimates were graded very low confidence, and two large trial databases could not be screened record by record.
Host 1So the drugs take some lean tissue with the fat, and nobody can yet rank them. The deep dive is out this week.
Waistlines in seventy countries
Host 1Now young people and body fat. Doctors usually go by body mass index, so what happens if you measure the waist as well?
Host 2This study used World Health Organization surveys from seventy countries: sixty thousand six hundred people aged fifteen to twenty-nine, measured between twenty ten and twenty twenty-three. Adding waist size and waist-to-height ratio, as a recent Lancet Commission recommends, about one in three had excess body fat. Only about thirteen percent had obesity by body mass index, while nearly sixteen percent had a large waist and a body mass index that looked fine.
Host 1Does a big waist at twenty actually mean anything for health?
Host 2People with excess adiposity had about twice the odds of at least one of high blood pressure, diabetes or high cholesterol, and four times the odds of several. The waist-only group, had nearly double the odds of at least one.
Host 1What can a study like this not tell us?
Host 2It is a snapshot, so it shows association, not that the waist causes the risk, and it follows nobody forward in time. Countries differ enormously, from under seven percent in Ethiopia to over seventy-seven in Tonga.
Host 1So a tape measure catches risk that body mass index misses, even in teenagers. That deep dive is out this week.
Cholesterol drugs and first heart attacks
Host 1Next, cholesterol drugs for people who have never had a heart attack. With statins and several newer drugs available, which ones actually prevent the first one?
Host 2A network meta-analysis combined twenty-nine randomised trials with about two hundred and nineteen thousand participants, split by baseline risk. The clearest pattern was that benefit followed statin intensity: in lower-risk people, high-intensity statins cut major cardiovascular events by about forty-seven percent and moderate-intensity statins by about twenty-four.
Host 1And what about the newer drugs that get added on top of a statin?
Host 2In high-risk people, adding the injectable evolocumab cut events about twenty-six percent more than the statin alone. Bempedoic acid, an option for people who cannot tolerate statins, cut events by about thirty-six percent against no treatment. The fish-oil derivative EPA and fibrates showed no clear added benefit.
Host 1How much weight should a listener put on those numbers?
Host 2Certainty was low or very low for twenty-three of twenty-seven comparisons, and the network's consistency could not be tested. Bempedoic acid rests on the primary-prevention group of a single trial, about two thousand people. And these are relative reductions: first events typically strike one to three percent of such people a year, so absolute gains are smaller than the percentages sound.
Host 1So statin intensity comes first, and add-ons matter mainly at high risk. The deep dive is out this week.
Is the Atlantic too fragile in models?
Host 1Now the Atlantic overturning circulation, which carries warm water north toward Europe. We usually hear that models underestimate the risk of collapse; does this paper ask the opposite?
Host 2Yes. In the latest generation of climate models run out to the year twenty-three hundred, the deep part of the circulation shuts down in at least one model under every emission scenario, and in every model under the highest. Two Southampton oceanographers, one of whom led that analysis, ask whether some of those models collapse too easily.
Host 1What makes them suspect the models are too eager?
Host 2Direct measurements at twenty-six degrees north since two thousand four show only a weak downward trend, barely statistically significant. Some of the collapsing models are also known to warm too strongly and react too strongly to cleaner air. They argue the chain starts when deep winter mixing south of Greenland shuts off, and that coarse models may let that happen too readily.
Host 1So is this good news for Denmark?
Host 2Not yet. This is a perspective piece and a preprint, with no new simulations; it proposes tests rather than results. The authors also list real warning signs, including a two-decade decline in the deep return current and the largest North Atlantic freshening in over a century.
Host 1So the worry has flipped from too stable to possibly too fragile, with no answer yet. The deep dive is out this week in the feed.
A word from our sponsor
Host 1This episode is brought to you by Thermos. The vacuum flask that keeps your coffee hot all morning.
Host 2Inside every Thermos, warm coffee flows north along the top, cools, sinks at the far wall and returns south along the bottom. A complete overturning circulation, in half a litre.
Host 1Thermos has not paid for this, has not been asked, and as far as we know has never heard of us.
Host 2I keep mine in the hallway. The umbrella stand now has a mild maritime climate.
Host 1Every flask is checked against two decades of observations and shows no significant downward trend.
Host 2Thermos. Unscrew the lid, and Northern Europe stays temperate.
A nickel superconductor without pressure
Host 1Last, materials physics. Superconductors carry current with zero resistance, so what is new about this nickel compound?
Host 2Nickel oxides have superconducted before, but only under enormous pressure or as thin films strained on a substrate. This group grew bulk crystals of a four-layer lanthanum nickel oxide under high pressure, then chemically pulled oxygen out of them. The result superconducts at ordinary pressure, starting at about eighteen kelvin.
Host 1Eighteen kelvin sounds extremely cold. Why does it matter?
Host 2It is about minus two hundred and fifty-five degrees Celsius, too cold for practical use; what matters is a bulk crystal that can be measured properly: resistance, magnetic shielding of about sixty percent of the volume, and a jump in heat capacity all put the transition at the same temperature, which rules out a thin surface effect.
Host 1What should we hold back on until other labs check it?
Host 2It is a preprint from one group, not yet peer reviewed. The best crystals weighed about a hundredth of a milligram, and larger ones superconducted through less of their volume, because the oxygen removal does not reach all the way in.
Host 1So a clean bulk platform to study, not a practical material. Its deep dive is out this week in the feed.
Sign-off
Host 1That is the Hastrup Review of Science for this week.
Host 2Read the papers, check the numbers, and we will see you next week.
Deep dives from this episode
- Caffeine on the Blocks, How Much Makes Sprinters FasterDeep dive · 18 min
- Weight-Loss Drugs and the Lean Mass That Goes With the FatDeep dive · 21 min
- The Waist the Scale Misses in Young PeopleDeep dive · 20 min
- Which Cholesterol Drugs Prevent a First Heart AttackDeep dive · 16 min
- Do Climate Models Give Up on the Atlantic Too Easily?Deep dive · 21 min
- Four Layers of Nickel, Superconducting Without the SqueezeDeep dive · 20 min
Sponsor: RefurbMiner — free 14-day trial (reklamelink)